A single point mutation of the GABAA receptor α5-subunit confers fluoxetine sensitivity

Neuropharmacology

Volumn 52, Issue 2, 2007, Pages 497-505

  Derry, Jason M C ^a   Paulsen, Isabelle M ^a   Davies, Martin ^a   Dunn, Susan M J ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Allosteric modulation; Chimera; Fluoxetine; GABAA receptor; Mutagenesis

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 4 PIPERIDINESULFONIC ACID; ALANINE; AMINO ACID; FLUOXETINE; GABOXADOL; ISOPROTEIN; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG;

ALLOSTERISM; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CHIMERA; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; MOLECULAR MODEL; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; STRUCTURAL PROTEOMICS;

AMINO ACID SUBSTITUTION; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRIC STIMULATION; FLUOXETINE; GABA AGONISTS; GAMMA-AMINOBUTYRIC ACID; ISOXAZOLES; MEMBRANE POTENTIALS; MODELS, MOLECULAR; MUTAGENESIS; MUTATION; OOCYTES; PATCH-CLAMP TECHNIQUES; PROTEIN SUBUNITS; RECEPTORS, GABA-A; RECOMBINANT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; XENOPUS LAEVIS;

EID: 33846316694     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.07.036     Document Type: Article

References (32)

1. A receptors: classification on the basis of subunit structure and function. Pharmacol. Rev. 50 (1998) 291-313
2. Brejc K., van Dijk W.J., Klaassen R.V., Schuurmans M., van der Oost J., Smit A.B., and Sixma T.K. Crystal structure of an Ach-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 411 (2001) 269-276
3. Celie P.N.H., van Rossum-Fikkert S.E., van Dijk W.J., Brejk K., Sixma T.K., and Smit A.B. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron 41 (2004) 907-914
4. Colquhoun D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br. J. Pharmacol. 125 (1998) 924-947
5. A receptor structure relieved by AChBP. Trends Biochem. Sci. 27 (2002) 280-287
6. Derry J.M.C., Dunn S.M.J., and Davies M. Identification of a residue in the γ-aminobutyric acid type A receptor α subunit that differentially affects diazepam-sensitive and -insensitive benzodiazepine site binding. J. Neurochem. 88 (2004) 1431-1438
7. A receptor α6 subunit. J. Pharmacol. Exp. Ther. 309 (2004) 1108-1115
8. Eisenamer B., Rammes G., Gimpl G., Shapa M., Ferrari U., Hapfelmeier G., Bondy B., Parsons C., Gilling K., Zieglgänsberger W., Holsboer F., and Rupprecht R. Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptors. Mol. Psychiatry 8 (2003) 994-1007
9. A receptors: limits, insights, future developments. Neuroscience 119 (2003) 933-943
10. A receptor extracellular and transmembrane domains: important insights in pharmacology and function. Mol. Pharmacol. 68 (2005) 1291-1300
11. Farrar S.J., Whiting P.J., Bonnert T.P., and Mckernan R.M. Stoichiometry of a ligand-gated ion channel determined by fluorescence energy transfer. J. Biol. Chem. 274 (1999) 10100-10104
12. Garćia-Colunga J., Awad J.N., and Miledi R. Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2041-2044
13. Goldin A.L. Maintenance of Xenopus laevis and oocyte injection. Methods Enzymol. 207 (1992) 266-279
14. Griffin L.D., and Mellon S.H. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 13512-13517
15. Hansen S.B., Sulzenbacher G., Huxford T., Marchot P., Taylor P., and Bourne Y. Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations. EMBO J. 24 (2005) 3635-3646
16. A receptors: discrete binding sites underlie subtype specificity. Nat. Neurosci. 6 (2003) 362-369
17. A receptor by replacement of several divergent amino-terminal regions with the α1 counterparts. Br. J. Pharmacol. 120 (1997) 559-564
18. Kash T.L., Trudell J.R., and Harrison N.L. Structural elements involved in activation of the gamma-aminobutyric acid type A (GABAA) receptor. Biochem. Soc. Trans. 32 (2004) 540-546
19. A receptors. Prog. Neurobiol. 67 (2002) 113-159
20. A receptor. Mol. Pharmacol. 57 (2000) 932-939
21. Moore K.R., and Blakely R.D. Restriction site-independent formation of chimeras from homologous neurotransmitter-transporter cDNAs. BioTechniques 17 (1994) 130-136
22. Newell J.G., Davies M., Bateson A.N., and Dunn S.M.J. Tyrosine 62 of the γ-aminobutyric acid type A receptor b2 subunit is an important determinant of high affinity agonist binding. J. Biol. Chem. 275 (2000) 14198-14204
23. 191 segment is involved in GABA binding and channel gating. J. Biol. Chem. 278 (2003) 13166-13172
24. Olsen R.W., Chang C.S., Li G., Hanchar H.J., and Wallner M. Fishing for allosteric sites on GABA(A) receptors. Biochem. Pharmacol. 68 (2004) 1675-1684
25. O'Shea S.M., and Harrison N.L. Arg-274 and Leu-277 of the γ-aminobutyric acid type A receptor α2 subunit define agonist efficacy and potency. J. Biol. Chem. 275 (2000) 22764-22768
26. Pinna G., Costa E., and Guidotti A. Fluoxetine and norfluoxetine stereospecifically facilitate pentobarbital sedation by increasing neurosteroids. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 6222-6225
27. A receptor activity through a novel modulatory site. J. Pharmacol. Exp. Ther. 304 (2003) 978-984
28. A receptors. Trends Pharmacol. Sci. 18 (1997) 425-429
29. A receptor subtype. J. Neurosci. 17 (1997) 2728-2737
30. Ugale R.R., Mittal N., Hirani K., and Chopde C.T. Essentiality of central GABAergic neuroactive steroid allopregnanolone for anticonvulsant action of fluoxetine against pentylenetetrazole-induced seizures in mice. Brain Res. 1023 (2004) 102-111
31. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4Å resolution. J. Mol. Biol. 346 (2005) 967-989
32. Vaswani M., Linda F.K., and Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog. Neuropsychopharmacol. Biol. Psychol. 27 (2003) 85-102